IL6 and hepatocellular carcinoma: Taken together, these data suggest that high expression of IL-6 and hTERT may contribute to poor outcomes in patients with HCC and that pharmacological inhibition of the IL-6/STAT3/TERT signaling axis with atorvastatin may improve patient outcomes by inducing HCC cell senescence in vivo.